Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Oct 15.

Published in final edited form as: J Pharm Biomed Anal. 2017 Sep 11;148:65–72. doi: 10.1016/j.jpba.2017.09.013

Table 5.

The concentration (mean ± SD, n = 4, ng/ml) of those compounds only detected at certain time points in the PK study.

Analyte	Time (min)
	15	30	45	60	120	240

Erlotinib	147.1 ± 62.2	123.7 ± 45.0	119.5 ± 97.6	87.6 ± 87.6	23.0 ± 37.7^a	14.4 ± 24.9^a
Sunitinib	9.4 ± 12.1^a	18.4 ± 10.6^a	22.8 ± 18.9^a	12.7 ± 20.0^a	14.7 ± 15.8^a	ND
Dasatinib	9.1 ± 18.2^a	21.5 ± 19.2^a	34.3 ± 41.6^a	24.8 ± 49.7^a	18.4 ± 23.1^a	10.1 ± 20.2^a
Lapatinib	8.8 ± 12.7^a	16.3 ± 28.2^a	21.4 ± 25.6^a	21.2 ± 25.7^a	20.1 ± 28.2^a	18.1 ± 25.4^a
Nilotinib	62.1 ± 32.8	59.1 ± 31.4	69.0 ± 37.2	68.8 ± 26.8	67.3 ± 64.3	34.6 ± 33.1^a
Axitinib	51.7 ± 40.0	42.7 ± 19.3	46.1 ± 39.6	34.2 ± 37.3	11.1 ± 16.4^a	4.8 ± 26.8^a
Imatinib	53.1 ± 20.1	55.7 ± 28.6	68.8 ± 63.8	48.1 ± 56.9	19.9 ± 19.0^a	11.1 ± 19.2^a
Gefitinib	24.7 ± 22.0	32.4 ± 28.1^a	36.7 ± 41.5^a	33.2 ± 42.7^a	21.8 ± 25.5^a	32.7 ± 26.3^a

ND, not detected.

^a

concentrations for some mouse blood samples fell below the quantification limit, for which zero was used to replace the actual numbers.